(PRWEB) June 26, 2012
Parker Waichman LLP, a national law firm dedicated to protecting the rights of victims injured by defective drugs, has filed lawsuit on behalf of a Virginia man who took Actos and developed bladder cancer. The suit was filed in the U.S. District Court for the Western District of Louisiana on June 14th (Case No. 6:12-cv-1704). The case is one of many pending in the Actos multidistrict litigation (MDL No. 6:11-md-2299). Proceedings are taking place before Judge Rebecca F. Doherty. Jerrold S. Parker, co-founder of Parker Waichman, has been appointed to the Plaintiffs’ Steering Committee. (http://www.lawd.uscourts.gov/MDL2299; http://www.lawd.uscourts.gov/MDL2299/html/news.html)
According to the complaint, the Plaintiff took Actos as prescribed from 2006 to 2011 before developing bladder cancer. The lawsuit alleges that the Defendants knew that using Actos for an extended period of time would expose patients to an increased risk of bladder cancer, but did not notify its consumers. The complaint asserts that the Plaintiff would not have taken the drug if he was fully informed of its risks. As a result of the Defendants’ alleged actions or inaction, the Plaintiff now suffers from
- severe mental and physical pain and suffering
- past and future permanent injuries and emotional distress
- economic loss due to medical expenses
- living related expenses as a result of now having to live with bladder cancer
- loss of consortium
Specifically, the suit points out the fact that the Defendants have yet to alert their customers to the increased risk of bladder cancer associated with using the medication for one year. Last June, the U.S. Food and Drug Administration (FDA) warned about this link in a Safety Announcement and subsequently updated Actos’ safety information. Based on data from a 10 year ongoing study by Kaiser Permanente, the agency said that patients taking Actos for one year were 40 percent more likely to develop bladder cancer compared to those who have never taken the medication and noted that the risk increased with both duration and dosage. Previously, the FDA had announced an increased risk after two years of exposure. [http://www.fda.gov/Drugs/DrugSafety/ucm259150.htm; http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm
Actos was pulled from the market in France and Germany last June; according to the suit, data from the French Medicines Agency indicated an increased risk of bladder cancer in male patients who took the drug for at least a year.
In April, Health Canada modified the warning label on Actos to include the possible increased risk of bladder cancer with continual exposure. Late last month, a Canadian study published in the British Medical Journal found a two-fold increased risk of bladder cancer in patients who took the drug for at least two years. [hc-sc.gc.ca/dhp-mps/medeff/advisories-avis/public/_2012/actos_3_pc-cp-eng.php]
Actos is a type 2 diabetes medication that has been on the US market since 1999. It was jointly launched by Takeda and Eli Lilly, but according to the lawsuit, Takeda announced the end of this collaboration in April 2006. The suit also states that Actos is one of Takeda’s top-selling drugs with global sales of $4.8 billion last year; in 2008, Actos was the 10th best -selling medication in the United States.
Parker Waichman LLP continues to offer free legal consultations to victims of Actos. If you or a loved one were diagnosed with bladder cancer after taking Actos, please contact their office by visiting the firm's Actos injury page at http://www.yourlawyer.com. Free case evaluations are also available by calling 1 800 LAW INFO (1-800-529-4636).
For more information regarding Actos side effect lawsuits and Parker Waichman LLP, please visit http://www.yourlawyer.com or call 1-800-LAW-INFO (1-800-529-4636).
Parker Waichman LLP
Gary Falkowitz, Managing Attorney